The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Heparan Sulfate in Perlecan Promotes Mouse Atherosclerosis: Roles in Lipid Permeability, Lipid Retention, and Smooth Muscle Cell Proliferation
Abstract
Heparan sulfate (HS) has been proposed to be antiatherogenic through inhibition of lipoprotein retention, inflammation, and smooth muscle cell proliferation. Perlecan is the predominant HS proteoglycan in the artery wall. Here, we investigated the role of perlecan HS chains using apoE null (ApoE0) mice that were cross-bred with mice expressing HS-deficient perlecan ( Hspg2 Δ3/Δ3 ). Morphometry of cross-sections from aortic roots and en face preparations of whole aortas revealed a significant decrease in lesion formation in ApoE0/ Hspg2 Δ3/Δ3 mice at both 15 and 33 weeks. In vitro, binding of labeled mouse triglyceride-rich lipoproteins and human LDL to total extracellular matrix, as well as to purified proteoglycans, prepared from ApoE0/ Hspg2 Δ3/Δ3 smooth muscle cells was reduced. In vivo, at 20 minutes influx of human 125 I-LDL or mouse triglyceride-rich lipoproteins into the aortic wall was increased in ApoE0/ Hspg2 Δ3/Δ3 mice compared to ApoE0 mice. However, at 72 hours accumulation of 125 I-LDL was similar in ApoE0/ Hspg2 Δ3/Δ3 and ApoE0 mice. Immunohistochemistry of lesions from ApoE0/ Hspg2 Δ3/Δ3 mice showed decreased staining for apoB and increased smooth muscle α-actin content, whereas accumulation of CD68-positive inflammatory cells was unchanged. We conclude that the perlecan HS chains are proatherogenic in mice, possibly through increased lipoprotein retention, altered vascular permeability, or other mechanisms. The ability of HS to inhibit smooth muscle cell growth may also influence development as well as instability of lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Syndecans (13–16) and perlecan (14, 17, 18) have been shown to mediate the internalization of model remnant lipoproteins or TRL preparations enriched in LPL or apoE.”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“coupled with numerous cell culture studies by other groups over the years (13–19, 21), argue for independent action of proteoglycans in the hepatic clearance of triglyceride-rich remnants.”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Thus, we believe that the genetic data presented here and previously (9), coupled with numerous cell culture studies by other groups over the years (13–19, 21), argue for independent action of proteoglycans in the hepatic”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Response-to-Retention Hypothesis of Early Atherogenesis
Williams, K. J., & Tabas, I. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.551 · Cited by 1,413
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
Skålén, K., Gustafsson, M., Rydberg, E. K., Hultén, L. M., Wiklund, O., Innerarity, T. L., & Borén, J. (2002) · Nature · doi:10.1038/nature00804 · Cited by 1,019
Self-citationSuppression by heparin of smooth muscle cell proliferation in injured arteries
CLOWES, A. W., & KARNOWSKY, M. J. (1977) · Nature · doi:10.1038/265625a0 · Cited by 790
Supramolecular assembly of basement membranes
Timpl, R., & Brown, J. C. (1996) · BioEssays · doi:10.1002/bies.950180208 · Cited by 699
CD40 Signaling and Plaque Instability
Schönbeck, U., & Libby, P. (2001) · Circulation Research · doi:10.1161/hh2401.101272 · Cited by 566
Tangirala, R. K., Rubin, E. M., & Palinski, W. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39713-3 · Cited by 514
The Interaction between Human Plasma Lipoproteins and Connective Tissue Glycosaminoglycans
Iverius, P.-H. (1972) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)45469-0 · Cited by 461
Noonan, D. M., Fulle, A., Valente, P., Cai, S., Horigan, E., Sasaki, M., Yamada, Y., & Hassell, J. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54445-8 · Cited by 449
Heparan Sulfate: A Complex Polymer Charged with Biological Activity
Whitelock, J. M., & Iozzo, R. V. (2005) · Chemical Reviews · doi:10.1021/cr010213m · Cited by 410
Iozzo, R. V., Cohen, I. R., Grässel, S., & Murdoch, A. D. (1994) · Biochemical Journal · doi:10.1042/bj3020625 · Cited by 382
Proteoglycans in Atherosclerosis and Restenosis: Key Roles for Versican
Wight, T. N., & Merrilees, M. J. (2004) · Circulation Research · doi:10.1161/01.res.0000126921.29919.51 · Cited by 362
Self-citationJohnson, J. L., George, S. J., Newby, A. C., & Jackson, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506201102 · Cited by 352
Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice.
Nicoletti, A., Kaveri, S., Caligiuri, G., Bariéty, J., & Hansson, G. K. (1998) · Journal of Clinical Investigation · doi:10.1172/jci119892 · Cited by 301
Kallunki, P., & Tryggvason, K. (1992) · The Journal of cell biology · doi:10.1083/jcb.116.2.559 · Cited by 240
Self-citationHeparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney
Rossi, M. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg019 · Cited by 238
Boren, J., Lee, I., Zhu, W., Arnold, K., Taylor, S., & Innerarity, T. L. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1847 · Cited by 234
Self-citationFuki, I. V., Kuhn, K. M., Lomazov, I. R., Rothman, V. L., Tuszynski, G. P., Iozzo, R. V., Swenson, T. L., Fisher, E. A., & Williams, K. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119685 · Cited by 213
Apoptotic cell death in atherosclerosis
Littlewood, T. D., & Bennett, M. R. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200310000-00007 · Cited by 194
Lindner, V, Olson, N. E., Clowes, A. W., & Reidy, M. A. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116085 · Cited by 159
Carew, T. E., Pittman, R. C., Marchand, E. R., & Steinberg, D. H. (1984) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.4.3.214 · Cited by 143
Flood, C., Gustafsson, M. V., Pitas, R. E., Arnaboldi, L., Walzem, R. L., & Borén, J. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000117174.19078.85 · Cited by 141
Identification of the Proteoglycan Binding Site in Apolipoprotein B48
Flood, C., Gustafsson, M. V., Richardson, P. E., Harvey, S. C., Segrest, J. P., & Borén, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204053200 · Cited by 125
Identification of Sites in Domain I of Perlecan That Regulate Heparan Sulfate Synthesis
Dolan, M. A., Horchar, T., Rigatti, B. W., & Hassell, J. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4316 · Cited by 119
Development of experimental designs for atherosclerosis studies in mice
Daugherty, A., & Rateri, D. L. (2005) · Methods · doi:10.1016/j.ymeth.2004.11.008 · Cited by 118
Kunjathoor, V. V., Chiu, D. S., O’Brien, K. D., & LeBoeuf, R. C. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0302.105378 · Cited by 118
Pillarisetti, S., Paka, L., Obunike, J. C., Berglund, L., & Goldberg, I. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119602 · Cited by 112
Tran, P.-K., Tran‐Lundmark, K., Soininen, R., Tryggvason, K., Thyberg, J., & Hedin, U. (2004) · Circulation Research · doi:10.1161/01.res.0000117772.86853.34 · Cited by 100
Self-citationPerlecan Heparan Sulfate Proteoglycan
Fuki, I. V., Iozzo, R. V., & Williams, K. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909173199 · Cited by 95
Friedrich, M. V. K., Göhring, W., Mörgelin, M., Brancaccio, A., David, G., & Timpl, R. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3259 · Cited by 89
Bingley, J. A., Hayward, I. P., Campbell, J. H., & CAMPBELL, G. R. (1998) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(98)70167-3 · Cited by 87
Hollmann, J., Schmidt, A., Bassewitz, D. B. V., & Buddecke, E. (1989) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.9.2.154 · Cited by 80
Localization of Glycosaminoglycan Substitution Sites on Domain V of Mouse Perlecan
Tapanadechopone, P., Hassell, J. R., Rigatti, B. W., & Couchman, J. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1714 · Cited by 66
Atherosclerosis in perlecan heterozygous mice
Vikramadithyan, R. K., Kako, Y., Chen, G., Hu, Y., Arikawa‐Hirasawa, E., Yamada, Y., & Goldberg, I. J. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400019-jlr200 · Cited by 63
Guretzki, H.-J., Gerbitz, K.-D., Olgemöller, B., & Schleicher, E. D. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90137-6 · Cited by 62
Lipoprotein Modulation of Subendothelial Heparan Sulfate Proteoglycans (Perlecan) and Atherogenicity
Pillarisetti, S. (2000) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(00)00048-7 · Cited by 58
Duan, W., Paka, L., & Pillarisetti, S. (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-16 · Cited by 58
Pillarisetti, S., Obunike, J. C., & Goldberg, I. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.50.29760 · Cited by 53
Paka, L., Kako, Y., Obunike, J. C., & Pillarisetti, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.8.4816 · Cited by 51
Kinsella, M. G., Irvin, C. A., Reidy, M. A., & Wight, T. N. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.01.045 · Cited by 50
Self-citationReduced perlecan expression and accumulation in human carotid atherosclerotic lesions
Tran, P.-K., Agardh, H. E., Tran‐Lundmark, K., Ekstrand, J., Roy, J., Henderson, B., Gabrielsen, A., Hansson, G. K., Swedenborg, J., Paulsson‐Berne, G., et al. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.03.010 · Cited by 42
Self-citationHedin, U., Daum, G., & Clowes, A. W. (1998) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(98)70326-x · Cited by 39
Self-citationMiller, J. D., Cummings, J. A., Maresh, G. A., Walker, D. G., Castillo, G. M., Ngo, C., Kimata, K., Kinsella, M. G., Wight, T. N., & Snow, A. D. (1997) · Glia · doi:10.1002/(sici)1098-1136(199710)21:2<253::aid-glia8>3.0.co;2-7 · Cited by 38
Self-citationAcidic glycosaminoglycan, lipid and water contents in human coronary arterial branches
Murata, K., & Yokoyama, Y. (1982) · Atherosclerosis · doi:10.1016/0021-9150(82)90171-x · Cited by 36
Edwards, I. J., Wagner, J. D., Vogl-Willis, C. A., Litwak, K. N., & Cefalu, W. T. (2004) · Cardiovascular Diabetology · doi:10.1186/1475-2840-3-6 · Cited by 32
Oxidized LDL bind to nonproteoglycan components of smooth muscle extracellular matrices
Chang, M. Y., Potter‐Perigo, S., Wight, T. N., & Chait, A. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31645-x · Cited by 28
Self-citationEvidence That Reduced Heparan Sulfate Promotes Lipoprotein Binding to Subendothelial Matrix
Pillarisetti, S., Paka, L., Obunike, J. C., Berglund, L., & Goldberg, I. J. (1997) · Cited by 25
Stender, S., & Astrup, P. B. (1977) · Atherosclerosis · doi:10.1016/0021-9150(77)90103-4 · Cited by 20
Endogenous heparin activity deficiency: the ‘Missing Link’ in atherogenesis?
Engelberg, H. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00650-5 · Cited by 19
Schwenke, D. C. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.10.2150 · Cited by 15
Murata, K., Murata, A., & Yoshida, K. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)00049-x · Cited by 14
Lipid mediators that modulate the extracellular matrix structure and function in vascular cells
Camejo, G., Hurt‐Camejo, E., Olsson, U., & Bondjers, G. (1999) · Current Atherosclerosis Reports · doi:10.1007/s11883-999-0010-1 · Cited by 14
Research works printed but not linked: 4
- 10.1161/atvb.22.3.462 · doi:10.1161/atvb.22.3.462
- 10.1002/(SICI)1098-1136(199710)21:2<228::AID-GLIA6>3.0.CO;2-2 · DOI
- 10.1161/atvb.17.10.2150 · doi:10.1161/atvb.17.10.2150
- 10.1161/res.89.12.1092 · doi:10.1161/res.89.12.1092
Cited by
Borén, J., & Williams, K. J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000330 · Cited by 524
Self-citationMolecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 459
Stanford, K. I., Bishop, J. R., Foley, E. M., Gonzales, J. C., Niesman, I. R., Witztum, J. L., & Esko, J. D. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38251 · Cited by 226
Gordts, P. L. S. M., Foley, E. M., Lawrence, R., Sinha, R., Lameda-Diaz, C., Deng, L., Nock, R., Glass, C. K., Erbilgin, A., Lusis, A. J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.016 · Cited by 86
Manta, C.-P., Leibing, T., Friedrich, M., Nolte, H., Adrian, M., Schledzewski, K., Krzistetzko, J., Kirkamm, C., David Schmid, C., Xi, Y., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.058615 · Cited by 84
Metadata
- Authors
- Tran-Lundmark, K., Tran, P.-K., Paulsson-Berne, G., Fridén, V., Soininen, R., Tryggvason, K., Wight, T. N., Kinsella, M. G., Borén, J., & Hedin, U.
- Venue
- Circulation Research
- Published
- 2008-07-03
- Volume
- 103
- Issue
- 1
- Pages
- 43-52
- ISSN
- 0009-7330
- 1524-4571
- Cited by
- 39
- References
- 51
- Language
- en
- Update notices
- correction (2009-01-30)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.